Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Topical KINOSTAT™ ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus.

Kador PF, Webb TR, Bras D, Ketring K, Wyman M.

Vet Ophthalmol. 2010 Nov;13(6):363-8. doi: 10.1111/j.1463-5224.2010.00826.x.

2.

Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose.

Kador PF, Betts D, Wyman M, Blessing K, Randazzo J.

Am J Vet Res. 2006 Oct;67(10):1783-7.

PMID:
17014334
3.
4.

Posterior capsular opacification in diabetic and nondiabetic canine patients following cataract surgery.

Bras ID, Colitz CM, Saville WJ, Gemensky-Metzler AJ, Wilkie DA.

Vet Ophthalmol. 2006 Sep-Oct;9(5):317-27.

PMID:
16939460
5.

Canine cataracts, diabetes mellitus and spontaneous lens capsule rupture: a retrospective study of 18 dogs.

Wilkie DA, Gemensky-Metzler AJ, Colitz CM, Bras ID, Kuonen VJ, Norris KN, Basham CR.

Vet Ophthalmol. 2006 Sep-Oct;9(5):328-34.

PMID:
16939461
6.

Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes.

Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J.

Drugs R D. 2004;5(3):125-39. Review.

PMID:
15139774
7.

Progression of sugar cataract in the dog.

Sato S, Takahashi Y, Wyman M, Kador PF.

Invest Ophthalmol Vis Sci. 1991 May;32(6):1925-31.

PMID:
1903366
8.
9.

GP-1447, an inhibitor of aldose reductase, prevents the progression of diabetic cataract in rats.

Kawakubo K, Mori A, Sakamoto K, Nakahara T, Ishii K.

Biol Pharm Bull. 2012;35(6):866-72.

10.

Evaluation of advanced glycation end-products in diabetic and inherited canine cataracts.

Bras ID, Colitz CM, Kusewitt DF, Chandler H, Lu P, Gemensky-Metzler AJ, Wilkie DA.

Graefes Arch Clin Exp Ophthalmol. 2007 Feb;245(2):249-57.

PMID:
16896921
11.

Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175.

Sato S, Mori K, Wyman M, Kador PF.

Exp Eye Res. 1998 Feb;66(2):217-22.

PMID:
9533847
12.

Aldose reductase activity and glucose-related opacities in incubated lenses from dogs and cats.

Richter M, Guscetti F, Spiess B.

Am J Vet Res. 2002 Nov;63(11):1591-7.

PMID:
12428672
13.

Ocular manifestations of diabetes mellitus: diabetic cataracts in dogs.

Basher AW, Roberts SM.

Vet Clin North Am Small Anim Pract. 1995 May;25(3):661-76. Review.

PMID:
7660540
14.

Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract.

Ao S, Kikuchi C, Ono T, Notsu Y.

Invest Ophthalmol Vis Sci. 1991 Nov;32(12):3078-83.

PMID:
1834606
15.

The relationship of cataract maturity to intraocular pressure in dogs.

Leasure J, Gelatt KN, MacKay EO.

Vet Ophthalmol. 2001 Dec;4(4):273-6.

PMID:
11906663
16.

Ultrasonographic abnormalities in the eyes of dogs with cataracts: 147 cases (1986-1992).

van der Woerdt A, Wilkie DA, Myer CW.

J Am Vet Med Assoc. 1993 Sep 15;203(6):838-41.

PMID:
8226239
17.

Diabetic cataracts and flavonoids.

Varma SD, Mizuno A, Kinoshita JH.

Science. 1977 Jan 14;195(4274):205-6.

PMID:
401544
18.

Effects of one-week versus one-day preoperative treatment with topical 1% prednisolone acetate in dogs undergoing phacoemulsification.

McLean NJ, Ward DA, Hendrix DV, Vaughn RK.

J Am Vet Med Assoc. 2012 Mar 1;240(5):563-9. doi: 10.2460/javma.240.5.563.

PMID:
22332625
19.

Cataracts are not associated with retinal detachment in the Bichon Frise in the UK--a retrospective study of preoperative findings and outcomes in 40 eyes.

Braus BK, Rhodes M, Featherstone HJ, Renwick PW, Heinrich CL.

Vet Ophthalmol. 2012 Mar;15(2):98-101. doi: 10.1111/j.1463-5224.2011.00947.x. Epub 2011 Oct 3.

PMID:
22051106
20.

Aqueous humor fibrinolytic activity in dogs with cataracts.

Escanilla N, Leiva M, Monreal L, Ríos J, Peña T.

Vet Ophthalmol. 2013 Nov;16(6):409-15. doi: 10.1111/vop.12013. Epub 2012 Dec 12.

PMID:
23240635
Items per page

Supplemental Content

Write to the Help Desk